The therapeutic effect of SAMiRNA-AREG, reported in mouse models and characterized by the stable silencing of the AREG gene, resulting in a reduction in the side effects of conventional siRNA treatment of pulmonary fibrosis, has also been evaluated in renal fibrosis [50]. This evidence concerns the gene AREG and pulmonary fibrosis.